US: 43.9 million to be diagnosed with Asthma/COPD by 2016 Says New Forecast

Oct. 5, 2011 - PRLog -- The report “Asthma and COPD Therapies: World Market 2011-2021” available at http://www.pharmaceutical-market-research.com/publications/diseases_conditions/asthma/asthma_copd_therapies.html looks at how the market for asthma and COPD treatments will perform from 2011. The new report provides potential drug revenues to 2021, analysing opportunities and market prospects.

The 138 page report provides potential asthma and COPD drug revenues at total world, company, product and national levels. Through our research and analysis we aim to save you time and help in your decisions. Market prospects and outlooks are given for GSK, Merck, Boehringer Ingelheim, AstraZeneca, Novartis and Nycomed, including revenue forecasts.

The asthma/COPD market is a rising one with a large amount of momentum coming from COPD, which has remained a relatively unfamiliar disease. In 2009, 40.3 million Americans were diagnosed with asthma or COPD (chronic bronchitis and emphysema). Of these, 25.1 million had asthma and 15.1 million had COPD.

The report “Asthma and COPD Therapies: World Market 2011-2021” is available from Piribo at:
http://www.pharmaceutical-market-research.com/publication...

Piribo product ID: VIS00317

About Piribo

Piribo is the source for information products concerning the global biotechnology and pharmaceutical industries. Here you can browse and buy thousands of business information studies, market reports and books. Piribo has ongoing relationships with leading market research and publishing companies, so we can offer you a current and comprehensive range of specialised intelligence.

# # #

About Piribo.
Piribo http:www.piribo.com is the source for information products concerning the global biotechnology and pharmaceutical industries. Here you can browse and buy thousands of business information studies, market reports and books.